November 4, 2003

MEDICAID DRUG REBATE PROGRAM

RELEASE #127

For State Medicaid Directors

NEW LABELERS

Labeler Name/Labeler Code	Mandatory Coverage <u>Date</u>	Optional Coverage <u>Date</u>
World Gen (Labeler Code 66814)	01/01/2004	09/05/2003
Carolina Pharmaceuticals, Inc. (Labeler Code 68249)	01/01/2004	09/22/2003
Purdue Pharmaceutical Products, L.P. (Labeler Code 67781)	01/01/2004	09/24/2003
Alaven Pharmaceutical, LLCP. (Labeler Code 68220)	01/01/2004	10/03/2003
Genta, Inc. (Labeler Code 66657)	01/01/2004	10/08/2003
Cubist Pharmaceuticals, Inc. (Labeler Code 67919)	01/01/2004	10/24/2003

REINSTATED LABELER

Imiren Pharmaceuticals, Inc., Labeler Code 61808, has signed a new rebate agreement and will be reinstated in the drug rebate program effective 01/01/2004.

TERMINATED LABELERS

The following labeler codes are being terminated effective January 1, 2004:

E. Fougera and Co., Division of Altana (Labeler Code 00168); Delta Pharmaceuticals, Inc. (Labeler Code 53706); RIJ Pharmaceutical Corporation (Labeler Code 53807); Trigen Laboratories, Inc. (Labeler Code 59746); and Nnodum Corporation (Labeler Code 63044).

The following labeler code is being voluntarily terminated effective January 1, 2004:

Genderm (Labeler Code 52761); and Baxter Healthcare Corporation (Labeler Code 62338).

OTHER ATTACHMENT

A copy of the current listing of the 90-day treasury bill auction rates beginning with the period April 22, 2002, is attached.

Please remember to direct your drug rebate questions to a staff member listed in section "O" of the <u>Medicaid Drug Rebate Operational Training Guide</u>.

Wayne Smith Acting Director Finance, Systems and Budget Group Center for Medicaid and State Operations

Attachment

cc: All State Drug Rebate Technical Contacts All Regional Administrators

WEEKLY U.S. T-BILL DISCOUNT RATE

Date of	Discount	Date of	Discount] [Date of	Discount
Auction	Rate	Auction	Rate		Auction	Rate
04-22-02	1.720	11-18-02	1.227		06-16-03	0.854
04-29-02	1.760	11-25-02	1.228] [06-23-03	0.830
05-06-02	1.773	12-02-02	1.231		06-30-03	0.903
05-13-02	1.781	12-09-02	1.215		07-07-03	0.907
05-20-02	1.760	12-16-02	1.219		07-14-03	0.895
05-28-02	1.760	12-23-02	1.207		07-21-03	0.911
06-03-02	1.752	12-30-02	1.207		07-28-03	0.964
06-10-02	1.752	01-06-03	1.207		08-04-03	0.964
06-17-02	1.732	01-13-03	1.199		08-11-03	0.960
06-24-02	1.712	01-21-03	1.179	1 [08-18-03	0.964
07-01-02	1.719	01-27-03	1.159	1 [08-25-03	0.997
07-08-02	1.724	02-03-03	1.175	1 [09-02-03	0.988
07-15-02	1.712	02-10-03	1.171	1 [09-08-03	0.951
07-22-02	1.692	02-18-03	1.179	1 [09-15-03	0.947
07-29-02	1.712	02-24-03	1.195	1 [09-22-03	0.953
08-05-02	1.627	03-03-03	1.198	1 [09-29-03	0.953
08-12-02	1.659	03-10-03	1.077	1 [10-06-03	0.939
08-19-02	1.659	03-17-03	1.137	1 [10-14-03	0.923
08-26-02	1.661	03-24-03	1.174	1 [10-20-03	0.939
09-03-02	1.639	03-31-03	1.121	1 [10-27-03	0.960
09-09-02	1.676	04-07-03	1.158		11-03-03	0.960
09-16-02	1.692	04-14-03	1.186			
09-23-02	1.639	04-21-03	1.182			
09-30-02	1.566	04-28-03	1.141	1 [
10-07-02	1.615	05-05-03	1.117			
10-15-02	1.659	05-12-03	1.089] [
10-21-02	1.696	05-20-03	1.040] [
10-28-02	1.578	05-28-03	1.121	1 [
11-04-02	1.433	06-02-03	1.133] [
11-12-02	1.211	06-09-03	1.024			

weekly 90-day treasury bill auction rates

TOPICAL INDEX - STATE MEDICAID RELEASES 1 - 127

TOPIC	RELEASE #
1A Drug Listing	11
Additional Copies of Releases to SMDs	40
Adjustment Code for Forms CMS-304 & CMS-304a	57
Allscrips Pharmaceuticals, Inc.	65, 68, 69
AMP Recalculations	107, 109, 110. 112
Bankruptcy - Drug Labelers	19, 61, 68
Best Price to DSH Covered Entities	36
Betaseron - Coverage & Reimbursement	38, 40
Bulk Transfer/Buy-Out of Major Pharm. Assets	54, 55
Calphron	76, 79
Caverject Coverage	55
Closure During Federal Furloughs	57
Compendia	70
Confidential Information Release	17
	23
Constant Disputes by Drug Labelers Contact Information	65, 92
CPI-U Information	09, 102
	41
Dataset Name Changes on Quarterly Rebate Tapes	123
Deleted NDCs (non-rebatable)	26
Dipyridamole Issue	20
Dispute Resolution: Definition	19
Issues	55, 65, 71, 86, 108
Meetings	100, 104, 113, 117, 123
Process Stages Transfer of Function	45 121
Web Site	121 122
	42
Workgroup Survey Results	42 59
Dispute Resolutions	
Drug Category Change	61, 76
Drug Efficacy Study & Implementation (DESI):	20
Change Effective Date Change Schedule	18
Effective Date Revisions	23, 24
	23, 24 70
DRUGDEX, a new compendium	65
Drug Emporium, Inc. Effective Date Duplicate Discount/Rebate Mechanism Implementation	33
-	97
Effective Date(s) of Rebate Agreements	30
Enteral Nutritional Products - Coverage Enteral Products	30 19
Eon Labs Product	117 43
Experimental Drugs - Coverage	43
Failure of Manufacturers to Notify States of Disputes or Pay Population	63
Disputes or Pay Rebates	
FDA/MDRI Data Match	107, 115
Generic Substitution Laws	67 DELEASE #
TOPIC	RELEASE #

Goldline OTC Vitamin Haldol Rebates Herceptin: Genentech New Product HIPPA – Prescription Numbers Hotline HRSA Notice Published/Exclusion File Improper Rebate Withholding/Interest Implications Index for Drug Rebate Notes Information Sharing Interest Calculation under Section V(b)	102 75 85 124 53 98, 101, 106 114 31 57 29, 88, 98
Interest:	
Failure to Pay	65
When PPAs are Submitted	121
Internet:	
Home Page	61, 85, 105, 117
Prescription Reimbursement Information	123
Pharmacy Plus Demonstrations	123
Invoices:	26
Correct Labeler Address	36
Format	03
Incomplete Drug Labeler Data	18
Incorrect Invoicing Demitteness Advise Demort Surgery	26 25
Remittance Advice Report Survey Submission	35 19
Submitting for Multiple Quarters	36
Submitting to Drug Labelers	28
Labeler Contact File Changes	28 26, 32
Lovenox Prefilled Syringes	20, 32 91
LTE/IRS Drugs	26
Magnetic Media	20
New Address for Shipping (Effective 6/1/95)	52
Rejections	15
Shipments	15, 23
Specification Revisions	14, 72, 73
Manufacturer Information Record Specification	20
Manufacturer Name & Address Contact Info Diskette	27
MDR Technical E-mail Address	124
Medical Supplies & Devices	03, 16, 26
Metric Conversion/Rounding	18
Multiple Package Size-Pricing Inconsistency	123
New Drug Products	41
New Rebate Agreement Status	23
Novartis Rounding All URAs Back to 1991	117
OBRA '93	40
OIG Reports/Reviews	120
Overpayments Due to AMP Recalculations	57, 107
Personnel Changes	124
PHS Drug Pricing Program	44
TOPIC	RELEASE #

	o 7
Point-of-Sale System (POS) in Pharmacies	85
Policy E-Mail Address	113, 117
Prior Authorization	55
Prior Period Adjustments	14, 16, 60, 87
Prior Period Adjustments - Eli Lilly & Company	37
Prior Quarter Adjustment Statement (PQAS) Approval	60
Proposed Discount Equal Access Legislation	51
Publication of Drug Rebate Regulations CMS-2175-FC	126
Publication of Drug Rebate Regulations MB-46-P	55
Quarterly Prices, Late Submission	33
Quarterly Reporting - Form CMS-64.r	40
Quarterly Tape Submission to CMS	60, 72
Quarterly Update File	14
Questions and Answers	65
Rebate Agreements:	
Start Date Procedures	102
Separate/Supplemental	102
Rebate/Reimbursement Issues	64, 113
Rebates:	01,110
Calculation Formula	07
Drugs Purchased Through the FSS	113
Less than Administrative Costs	40
Nonpayment	94
Partial Payments	55
Remittance/Check Address	30
Reconciliation of State Invoice (ROSI) Approval	60
	41
Rejection of State Records Matching LTE Drugs	
Remittance Advice Report/Workgroup	48, 52, 53, 56
Rescission of Termination for Novopharm USA	39 85
S-TAG (Systems Technical Advisory Group)	85
Separate Rebate Agreements with Manufacturers	38, 113
Special Advisory Group	16
Special Study – Anti-Load Viral/AIDS Drugs	102
Staff Listing	53
Staff Relocation	52, 83
Standard Summary Record Format	13
State Application of the FUL Program	48
State Contact Information	23, 26, 41, 98
State Coverage:	40
LTE & IRS Drugs	40
Unit-Dose Drugs	19
State Data Validation Edits	33
State Hearing Process	44
State Invoices Containing Universal Product Codes	51
State Pharmacy Assistance Programs-Revised Criteria	124
State Plan Amendment Requirement	47
State Responsibility - Terminated Drugs	19
State Utilization Data Study (SUDS)	33
TOPIC	RELEASE #

	70
Termination Date (NDC)	79
Terminated/Deleted Records	44
Termination From Program	55
Therapeutic Equivalency Code	64
Timely Receipt of Tapes/Notices of Mailing	45
Tolerance Threshold Clarification	
For Interest	48
Rebate Amount Adjustments	44
Training Guide	105, 109, 122, 124, 125
Unit-Dose Packaging	15
Unit Per Package Size	03
Change for Beohringer Ingelheim Product	123
Unit Rebate Amount (URA):	
Additional Amounts in 3/1998 File	85
Edits	43
Erroneous Amounts	51
Incorrect Amounts for 1Q98	79, 80
Invoice when the Amount is Zero	44
New Rounding Method	98, 100, 101, 106
Recalculations	111
Unit Type:	
Changes and Prior Period Adjustments	43
Conversion Date Changed	34
Revisions	32, 83
UPPS Less Than 1.0	19
UPPS Used for Calculating Utilization	61
Use of Information from Outside Sources	48
Utilization Adjustments for Prior Calendar Quarters	67, 72
Utilization Data:	<i>`</i>
Changes to Labelers	57
Corrections/Problems	18, 51, 72
Late Submission	18
Receipt	29, 31
Record Format	08, 13, 72
Set Naming Requirements	19
Tapes/Confirmation Letter	19, 30, 40, 45, 58, 72, 82
Transmitting Corrections/Adjustments to CMS	16, 40, 72
Utilization Tape Record Specification	67, 72, 73, 98, 105
Vaccine:	
Deletions	26
Exclusions	19, 23
Policy Clarification	25
Viagra Coverage	81
Vitasert	64
Warrick Pharmaceuticals (Sodium Chloride Solution)	98
Xenical Coverage	97
Y2K	72, 87
	, .,